BioSpace News Archive

Cosmos Holdings, Inc. announced it has appointed finance veteran Dr. Anastasios Aslidis to the Board of Directors and as a member of the Board’s audit committee.

Qualigen Therapeutics, Inc. (Nasdaq: QLGN), today announces it has entered into definitive agreements to acquire a majority stake in NanoSynex Ltd., an Israeli-based developer of next generation diagnostics technology.

Tierra Biosciences announced today that Michael Nemzek has joined the company as its new Chief Executive Officer

Co-Diagnostics, Inc. announced that it will be hosting a booth at the Medical Fair Brasil, held May 3-6, 2022, at the Expo Center Norte in São Paulo, Brazil.

DepYmed Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare diseases and oncology, based upon targeting the protein tyrosine phosphatase (PTP) family of enzymes.

Alcami, a leading United States-based contract development and manufacturing organization, announced that it is partnering with Civica Inc., a nonprofit pharmaceutical company focused on ensuring quality generic medicines are accessible and affordable to everyone.

Journey Biosciences, Inc. A new study recently published in the journal Diabetes Care continues to validate the role that specific biomarkers - advanced glycation endproducts (AGEs) - in predicting if a person with diabetes will develop kidney disease.

Jaguar Health, Inc. announced that it has completed filing of the final regulatory section with the U.S. Food and Drug Administration’s Center for Veterinary Medicine to support conditional new animal drug approval of the company’s oral plant-based drug candidate Canalevia to treat exercise-induced diarrhea in dogs.

GBS Inc., a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, announced that it will release its financial results for the third quarter ended March 31, 2022, shortly after the NASDAQ market close on Tuesday, May 10.

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will host a conference call to discuss financial results for its second quarter of fiscal 2022, ended March 31, 2021, on May 12, 2022 at 4:30 PM Eastern Time.